Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Rhea-AI Summary
Jyong Biotech (Nasdaq:MENS) announced it filed its Form 20-F annual report for the fiscal year ended December 31, 2025 with the SEC on May 14, 2026.
The filing is available on the company’s investor relations site and the SEC website, and shareholders can request a free hard-copy with audited consolidated financial statements.
Positive
- None.
Negative
- None.
News Market Reaction – MENS
In the May 15 session, MENS declined 3.37%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Market access update | Positive | +0.9% | Outlined competitive market access strategy for botanical drugs Botreso and PCP. |
| Mar 27 | Clinical/IP update | Positive | -4.0% | Shared Phase III safety data and IP position for plant-derived drug MCS-2. |
| Feb 12 | Phase II data | Positive | +0.7% | Reported Phase II efficacy and metabolic benefits for MCS-8 plus Asian entry plans. |
| Jan 30 | Biomarker analysis | Positive | -7.8% | Released biomarker and cholesterol data for MCS-8 (PCP) supporting broader potential. |
| Dec 19 | Trading activity note | Neutral | -4.7% | Addressed share price and volume moves after lock-up expiry and outlined pipeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically focused announcements have produced mixed reactions, with some positive trial updates followed by selloffs and others aligning with modest gains.
This announcement of the 2025 Form 20-F follows a series of clinically oriented and corporate updates. Since late 2025, Jyong Biotech has highlighted Phase II and III data for candidates such as MCS-8 and MCS®‑2, including a 27.3% prostate cancer incidence reduction and statistically significant lipid improvements. Prior news also addressed lock-up expiry–related trading volatility and market access strategies for botanical drugs. The new annual report, as previewed in the recent 20-F filing, consolidates these developments alongside detailed risk disclosures, including funding constraints and legal exposures.
Key Terms
form 20-f regulatory
securities and exchange commission regulatory
audited consolidated financial statements financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on May 14, 2026.
The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov.
The Company will provide a hard copy of annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company at ir@jyongbio.com .
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Investor Relations
WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214
